Literature DB >> 14628853

Dystonia: phenotypes and genotypes.

S B Bressman1.   

Abstract

Despite clinical and genetic complexity of dystonia, knowledge of primary torsion dystonia and dystonia-plus syndromes was recently expanded. Part of the category of primary dystonia includes genetic forms (DYT1, DYT6, DYT13). The DYTI mutation, with predominant limbs (95p. 100) and neck and trunk (25-35p. 100) involvement accounts for about 80p. 100 of the early onset cases in the Ashkenazi population and of 16-53p. 100 in the non- Ashkenazi population. The dystonia-plus group is defined by the association of parkinsonism (dopa-responsive-dystonia and rapid-onset dystonia-parkinsonism) or myoclonus (myoclonus-dystonia). Dopa-responsive-dystonia is a heterogeneous group with several causes (GCH1 mutations, compound mutations in GCH1, mutations in TH gene, or in 6-PTS gene). Differential diagnosis could be juvenile parkinsonism (parkin mutations). Epsilon-sarcoglycan mutation accounts for a sub-group of myoclonus-dystonia, but other genes are still unidentified. The vast majority of dystonia are sporadic and still unexplained. Functional imaging may bring new insights in disease mechanisms. Because of phenotypic overlaps, within dystonia, new classifications based on functional markers may emerge.

Entities:  

Mesh:

Year:  2003        PMID: 14628853

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  10 in total

Review 1.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.

Authors:  Tufan Naiya; Amar K Misra; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  J Neural Transm (Vienna)       Date:  2012-02-29       Impact factor: 3.575

Review 3.  Genetic and clinical features of primary torsion dystonia.

Authors:  Laurie J Ozelius; Susan B Bressman
Journal:  Neurobiol Dis       Date:  2010-12-17       Impact factor: 5.996

Review 4.  The functional neuroanatomy of dystonia.

Authors:  Vladimir K Neychev; Robert E Gross; Stephane Lehéricy; Ellen J Hess; H A Jinnah
Journal:  Neurobiol Dis       Date:  2011-02-12       Impact factor: 5.996

5.  Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice.

Authors:  Michelle E Page; Li Bao; Pierrette Andre; Joshua Pelta-Heller; Emily Sluzas; Pedro Gonzalez-Alegre; Alexey Bogush; Loren E Khan; Lorraine Iacovitti; Margaret E Rice; Michelle E Ehrlich
Journal:  Neurobiol Dis       Date:  2010-05-10       Impact factor: 5.996

Review 6.  Animal models of focal dystonia.

Authors:  Craig Evinger
Journal:  NeuroRx       Date:  2005-07

7.  Novel THAP1 sequence variants in primary dystonia.

Authors:  J Xiao; Y Zhao; R W Bastian; J S Perlmutter; B A Racette; S D Tabbal; M Karimi; R C Paniello; Z K Wszolek; R J Uitti; J A Van Gerpen; D K Simon; D Tarsy; P Hedera; D D Truong; K P Frei; S Dev Batish; A Blitzer; R F Pfeiffer; S Gong; M S LeDoux
Journal:  Neurology       Date:  2010-01-19       Impact factor: 9.910

Review 8.  Genomic identification of regulatory elements by evolutionary sequence comparison and functional analysis.

Authors:  Gabriela G Loots
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

Review 9.  Research priorities in spasmodic dysphonia.

Authors:  Christy L Ludlow; Charles H Adler; Gerald S Berke; Steven A Bielamowicz; Andrew Blitzer; Susan B Bressman; Mark Hallett; H A Jinnah; Uwe Juergens; Sandra B Martin; Joel S Perlmutter; Christine Sapienza; Andrew Singleton; Caroline M Tanner; Gayle E Woodson
Journal:  Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 3.497

Review 10.  Deep brain stimulation for torsion dystonia in children.

Authors:  Ron L Alterman; Michele Tagliati
Journal:  Childs Nerv Syst       Date:  2007-06-06       Impact factor: 1.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.